Compare
GeoVax Labs, Inc. vs Cartesian Therapeutics, Inc. vs Upstream Bio, Inc. vs Lipocine Inc.
| Latest fiscal year | GeoVax Labs, Inc. GOVX | Cartesian Therapeutics, Inc. RNAC | Upstream Bio, Inc. UPB | Lipocine Inc. LPCN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.49M | $2.80M | $2.85M | $1.98M |
| Revenue growth (YoY) | -37.1% | -92.8% | +20.4% | -82.3% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | -869.3% | n/m | n/m | -524.7% |
| Net margin | -862.3% | n/m | n/m | -487.1% |
| Net income | -$21.46M | -$130.30M | -$143.44M | -$9.63M |
| EPS (Diluted) | n/a | -$5.02 | -$2.66 | -$1.69 |
| Operating cash flow | -$21.47M | -$73.94M | -$133.28M | -$9.76M |
| Free cash flow | -$21.50M | -$79.39M | -$133.44M | n/a |
| Cash & equivalents | $3.09M | $125.14M | $101.58M | $5.21M |
| Total assets | $6.34M | $296.41M | $353.77M | $17.01M |
| Total liabilities | $2.52M | $422.65M | $14.00M | $2.53M |
| Shareholders' equity | $3.83M | -$126.24M | $339.77M | $14.48M |
| Return on year-end equity | -561.2% | n/a | -42.2% | -66.5% |
| Shares outstanding | 1.73M | 26.01M | 54.24M | 6.16M |
Revenue, most recent five fiscal years
| Fiscal year | GeoVax Labs, Inc. | Cartesian Therapeutics, Inc. | Upstream Bio, Inc. | Lipocine Inc. |
|---|---|---|---|---|
| Latest | $2.49M Ended 2025-12-31 | $2.80M Ended 2025-12-31 | $2.85M Ended 2025-12-31 | $1.98M Ended 2025-12-31 |
| 1 year earlier | $3.95M Ended 2024-12-31 | $38.91M Ended 2024-12-31 | $2.37M Ended 2024-12-31 | $11.20M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $26.00M Ended 2023-12-31 | $2.38M Ended 2023-12-31 | -$2.85M Ended 2023-12-31 |
| 3 years earlier | $81.5K Ended 2022-12-31 | n/a | n/a | $500.0K Ended 2022-12-31 |
| 4 years earlier | $385.5K Ended 2021-12-31 | n/a | n/a | $16.14M Ended 2021-12-31 |